2023
Streptococcus pyogenes Colonization in Children Aged 24–59 Months in the Gambia: Impact of Live Attenuated Influenza Vaccine and Associated Serological Responses
Keeley A, Groves D, Armitage E, Senghore E, Jagne Y, Sallah H, Drammeh S, Angyal A, Hornsby H, de Crombrugghe G, Smeesters P, Rossi O, Carducci M, Peno C, Bogaert D, Kampmann B, Marks M, Shaw H, Turner C, de Silva T. Streptococcus pyogenes Colonization in Children Aged 24–59 Months in the Gambia: Impact of Live Attenuated Influenza Vaccine and Associated Serological Responses. The Journal Of Infectious Diseases 2023, 228: 957-965. PMID: 37246259, PMCID: PMC10547459, DOI: 10.1093/infdis/jiad153.Peer-Reviewed Original ResearchMeSH KeywordsChildGambiaHumansImmunoglobulin GInfluenza VaccinesInfluenza, HumanStreptococcus pyogenesVaccines, AttenuatedConceptsQuantitative polymerase chain reactionLAIV groupInfluenza vaccineSerological responseOdds ratioDay 7Live attenuated influenza vaccineChildren Aged 24High-burden settingsAttenuated influenza vaccineControl group participantsBurden settingsGambian childrenNasopharyngeal swabsPoint prevalenceAged 24Polymerase chain reactionAsymptomatic colonizationNasopharyngeal colonizationIgG increaseControl groupDay 21Day 0LAIVS. pyogenes
2021
The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24–59 months in The Gambia: a phase 4, open label, randomised, controlled trial
Peno C, Armitage E, Clerc M, Balcazar Lopez C, Jagne Y, Drammeh S, Jarju S, Sallah H, Senghore E, Lindsey B, Camara J, Bah S, Mohammed N, Dockrell D, Kampmann B, Clarke E, Bogaert D, de Silva T. The effect of live attenuated influenza vaccine on pneumococcal colonisation densities among children aged 24–59 months in The Gambia: a phase 4, open label, randomised, controlled trial. The Lancet Microbe 2021, 2: e656-e665. PMID: 34881370, PMCID: PMC8632704, DOI: 10.1016/s2666-5247(21)00179-8.Peer-Reviewed Original ResearchMeSH KeywordsChildCoinfectionGambiaHumansInfluenza VaccinesInfluenza, HumanPneumococcal VaccinesStreptococcus pneumoniaeVaccines, AttenuatedConceptsPneumococcal densityRespiratory viral infectionsLAIV groupMiddle-income country populationsPneumococcal carriageRespiratory virusesControl groupDay 7Influenza vaccineViral infectionDay 21Asymptomatic respiratory viral infectionsHigher pneumococcal carriage ratesHigh pneumococcal carriageInfluenza vaccine programsNasopharyngeal pneumococcal carriagePneumococcal carriage rateUse of LAIVAttenuated influenza vaccineUpper respiratory tractInvestigator teamOpen labelRandomisation sequencePrimary outcomeCarriage prevalence